← Leaderboards
David R Gandara
University Of California Davis
$14,446,339
Attributed
$17,944,101
Total exposure
12
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,944,101 · 12
By mechanism
U10$8,089,661 · 2
N01$6,117,733 · 3
UG1$3,722,571 · 1
M01$14,136 · 4
P30$0 · 2
Top collaborators
- Richard Valicenti13 shared
Most similar at University Of California Davis
Same institution · by research overlap
- Teresa W-M Fan$8,146,213
- Helen K Chew$812,573
- Derick Lau$900,675
- Julie L Sutcliffe$12,858,724
- Walter Ladson Hinton$6,843,307
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsClinical ResearchResearch PersonnelMalignant NeoplasmsResourcesProgramsLaboratoriesCommunitiesCaliforniaMultidisciplinaryLeadershipPatient PopulationCancer PreventionAreaCancer ControlDesignTranslationsTumorPathologyMedical OncologyRadiation OncologyEnsureFacultyCancer Care
Grant awards (46)
UCDCCC NCTN UG1 PROGRAM$562,222
UG1 · FY2025 · CA · contact PI
UCDCCC NCTN UG1 PROGRAM$562,222
UG1 · FY2024 · CA · contact PI
UCDCCC NCTN UG1 PROGRAM$494,871
UG1 · FY2023 · CA · contact PI
UCDCCC NCTN UG1 PROGRAM$557,262
UG1 · FY2022 · CA · contact PI
UCDCCC NCTN UG1 PROGRAM$522,931
UG1 · FY2021 · CA · contact PI
UCDCCC NCTN UG1 PROGRAM$521,581
UG1 · FY2020 · CA · contact PI
UCDCCC NCTN UG1 PROGRAM$501,482
UG1 · FY2019 · CA · contact PI
UCDCCC NCTN U10 Program$623,007
U10 · FY2018 · CA · contact PI
UCDCCC NCTN U10 Program$592,771
U10 · FY2017 · CA · contact PI
UCDCCC NCTN U10 Program$626,991
U10 · FY2016 · CA · contact PI
UCDCCC NCTN U10 Program$630,226
U10 · FY2015 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$237,565
N01 · FY2015 · CA · contact PI
UCDCCC NCTN U10 Program$99,708
U10 · FY2015 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$987,691
N01 · FY2014 · CA · contact PI
UCDCCC NCTN U10 Program$700,250
U10 · FY2014 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$362,578
N01 · FY2013 · CA · contact PI
Southwest Oncology Group/University of California, Davis$314,015
U10 · FY2013 · CA · contact PI
TAS::75 0849::TAS EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$1,090,973
N01 · FY2012 · CA · contact PI
Southwest Oncology Group/University of California, Davis$316,002
U10 · FY2012 · CA · contact PI
Early Therapeutics Development with Phase II Emphasis$907,940
N01 · FY2011 · CA · contact PI
TAS::75 0849::TAS EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$469,566
N01 · FY2011 · CA · contact PI
Southwest Oncology Group/University of California, Davis$330,569
U10 · FY2011 · CA · contact PI
Southwest Oncology Group/University of California, Davis$299,556
U10 · FY2010 · CA · contact PI
Early Therapeutics Development with Phase II Emphasis$146,842
N01 · FY2010 · CA · contact PI
TAS:: 75 0850 ::TAS RECOVERY ACT - ACTNOW CLINICAL TRIAL 8155$942,533
N01 · FY2009 · CA · contact PI
Southwest Oncology Group/ University of California,$348,516
U10 · FY2009 · CA · contact PI
Early Therapeutics Development with Phase II Emphasis$103,623
N01 · FY2009 · CA · contact PI
Southwest Oncology Group/ University of California,$314,107
U10 · FY2008 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$868,422
N01 · FY2007 · CA · contact PI
Southwest Oncology Group/ University of California,$344,197
U10 · FY2007 · CA · contact PI
Southwest Oncology Group/ University of California,$25,000
U10 · FY2007 · CA · contact PI
Southwest Oncology Group/ University of California,$343,423
U10 · FY2006 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS-261622009$0
N01 · FY2006 · CM · contact PI
Southwest Oncology Group/ University of California,$387,416
U10 · FY2005 · CA
Southwest Oncology Group/ University of California$299,584
U10 · FY2004 · CA
SOUTHWEST ONCOLOGY GROUP/UNIVERSITY OF CALIFORNIA, DAVIS$108,773
U10 · FY2004 · CA
PHASE I TRIAL OF E7389 (HALICHONDRIN B ANALOG)IN PATIENTS WITH ADVANCEDSOLID TUM$7,554
M01 · FY2004 · RR
PHASE I STUDY OF STI571 IN PATIENTS WITH MALIGNANCIES &VARYING DEGREES OF LIV$4,590
M01 · FY2004 · RR
PHASE III TRIAL OF CISPLATIN &IRINOTECAN VS CISPLATIN &ETOPOSIDE IN PATIENTS W$1,212
M01 · FY2004 · RR
DOCETAXEL FOR METASTATIC BREAST CANCER IN PATIENTS AGED 70 YEARS &OLDER (&YOUN$780
M01 · FY2004 · RR
SOUTHWEST ONCOLOGY GROUP/UNIVERSITY OF CALIFORNIA, DAVIS$435,092
U10 · FY2003 · CA
SOUTHWEST ONCOLOGY GROUP/UNIVERSITY OF CALIFORNIA, DAVIS$326,804
U10 · FY2002 · CA
CORE--CLINICAL TRIALS SUPPORT UNIT$0
P30 · FY2002 · CA
CANCER THERAPEUTICS$0
P30 · FY2002 · CA
SOUTHWEST ONCOLOGY GROUP/UNIVERSITY OF CALIFORNIA, DAVIS$316,709
U10 · FY2001 · CA
SOUTHWEST ONCOLOGY GROUP/UNIVERSITY OF CALIFORNIA, DAVIS$306,945
U10 · FY2000 · CA